Reading Time: 2 minutes

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (TSX-V:MDX), announces that it has entered into an agreement to settle $372,071 of debt owed to an arm’s length trade creditor, subject to all relevant consents and approvals. Under the Debt Settlement Agreement, $372,071 of trade debt will be settled by the issuance of 3,103,878 units (“Unit(s)”) at a price of $0.12 per Unit. Each Unit comprises one fully paid common share and one share purchase warrant, exercisable for a period of two (2) years from the date of issue, to acquire a further common share at the price of $0.20. Regulatory and other consents will include acceptance from the TSX Venture Exchange.

MedX presently has 145,071,428 common shares issued and outstanding.

About MedX.

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contacts

Scott Spearn, President and CEO

MedX Health Corp
905-670-4428 ext 229